Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA.
In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins'), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.
Written by:
Rice KR, Koch MO, Cheng L, Masterson TA. Are you the author?
Department of Urology, Indiana University Medical Center, 535 North Barnhill Drive, Indianapolis, IN 46202, USA.
Reference: Expert Rev Anticancer Ther. 2012 Jul;12(7):981-90.
doi: 10.1586/era.12.75
PubMed Abstract
PMID: 22845413
UroToday.com Investigative Urology Section
